Discovery of candidate genes and pathways that may help explain fertility cycle stage dependent post-resection breast cancer outcome

2008 ◽  
Vol 118 (2) ◽  
pp. 345-359 ◽  
Author(s):  
Eun-Young Oh ◽  
Patricia A. Wood ◽  
Xiaoming Yang ◽  
William J. M. Hrushesky
2020 ◽  
Vol 183 (3) ◽  
pp. 607-616
Author(s):  
Waleed S. Al Amri ◽  
Diana E. Baxter ◽  
Andrew M. Hanby ◽  
Lucy F. Stead ◽  
Eldo T. Verghese ◽  
...  

Abstract Purpose More than a third of primary breast cancer patients are treated with cytotoxic chemotherapy, typically without guidance from predictive markers. Increased use of neoadjuvant chemotherapy provides opportunities for identification of molecules associated with treatment response, by comparing matched tumour samples before and after therapy. Our hypothesis was that somatic variants of increased prevalence after therapy promote resistance, while variants with reduced prevalence cause sensitivity. Methods We performed systematic analyses of matched pairs of cancer exomes from primary oestrogen receptor-positive/HER2-negative breast cancers (n = 6) treated with neoadjuvant epirubicin/cyclophosphamide. We identified candidate genes as mediators of chemotherapy response by consistent subclonal changes in somatic variant prevalence through therapy, predicted variant impact on gene function, and enrichment of specific functional pathways. Influence of candidate genes on breast cancer outcome was tested using publicly available breast cancer expression data (n = 1903). Results We identified 14 genes as the strongest candidate mediators of chemoresponse: TCHH, MUC17, ARAP2, FLG2, ABL1, CENPF, COL6A3, DMBT1, ITGA7, PLXNA1, S100PBP, SYNE1, ZFHX4, and CACNA1C. Genes contained somatic variants showing prevalence changes in up to 4 patients, with up to 3 being predicted as damaging. Genes coding for extra-cellular matrix components or related signalling pathways were significantly over-represented among variants showing prevalence changes. Expression of 5 genes (TCHH, ABL1, CENPF, S100PBP, and ZFHX4) was significantly associated with patient survival. Conclusions Genomic analysis of paired pre- and post-therapy samples resulting from neoadjuvant therapy provides a powerful method for identification of mediators of response. Genes we identified should be assessed as predictive markers or targets in chemo-sensitization.


2014 ◽  
Vol 144 (2) ◽  
pp. 379-389 ◽  
Author(s):  
Aurélie Ayme ◽  
Valeria Viassolo ◽  
Elisabetta Rapiti ◽  
Gérald Fioretta ◽  
Hyma Schubert ◽  
...  

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
James E Korkola ◽  
Ekaterina Blaveri ◽  
Sandy DeVries ◽  
Dan H Moore ◽  
E Shelley Hwang ◽  
...  

2011 ◽  
Vol 47 (10) ◽  
pp. 1537-1545 ◽  
Author(s):  
Renaud Sabatier ◽  
Jocelyne Jacquemier ◽  
François Bertucci ◽  
Benjamin Esterni ◽  
Pascal Finetti ◽  
...  

2019 ◽  
Vol 133 ◽  
pp. S14-S15
Author(s):  
S. Corradini ◽  
M. Pazos ◽  
D. Reitz ◽  
S. Schönecker ◽  
M. Niyazi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document